Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Pathologist
  • Explore Pathology

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Molecular Pathology
    • Infectious Disease
    • Digital Pathology

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Oncology
    • Histology
    • Cytology
    • Hematology
    • Endocrinology
    • Neurology
    • Microbiology & Immunology
    • Forensics
    • Pathologists' Assistants
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways
    • Workforce Trends

    Educational Resources

    • Guidelines & Recommendations
    • App Notes

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Profiles & Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
Subscribe
Subscribe

False

The Pathologist / Issues / 2014 / Oct / Targeting Postpartum Depression
Neurology Neurology Biochemistry and molecular biology Molecular Pathology

Targeting Postpartum Depression

Could identification of a new biomarker offer hope for mothers?

By Roisin McGuigan 10/01/2014 1 min read

Share

Postpartum depression (PPD) is the most common complication of childbirth. It affects around 13 percent of mothers and is associated with over a ten-fold increase in suicide risk compared with healthy individuals. Researchers from Canada and Germany now hope they can develop new treatment strategies through their discovery of a new biomarker (1).

Lead author of the study, Julia Sacher from the Max-Planck Institute for human cognitive and brain sciences in Leipzig, Germany, says PPD is an immense public health issue. “It is often not diagnosed and in many cases not adequately treated. A mother’s mental health and well-being have profound effects on her child’s physical and emotional development and impact the entire family,” she explained.

Sacher believes that the discovery of the biomarker – elevated monoamine oxidase A (MAO-A) in the brain – could open up new directions to improve diagnosis, treatment and effective prevention strategies.

The researchers used positron emission tomography (PET), to measure MAO-A density in the prefrontal and anterior cingulate cortex in the brain. They found that in women experiencing PPD, MAO-A values were 21 percent higher than in healthy controls. “Our data argue for clinical trials of MAO-A inhibitors for PPD, and the development of new, well tolerated MAO-A inhibitors that either rapidly wash out of the periphery or which have high brain to periphery concentrations,” says Sacher.

According to the study, the biomarker doesn’t just identify depression; substantial MAO-A binding changes were also observed in the subclinical group; women who did not meet the criteria for full PPD, but who reported increased crying and sadness. This group also showed elevated MAO-A levels in brain regions important for balancing emotions and mood, such as the prefrontal cortex and the anterior cingulate cortex. For the researchers, this was an interesting find. “Either these women will go on to develop PPD at some later time or they have some sort of compensation mechanism protecting them from developing the full-blown clinical disorder,” says Sacher. “Based on our neurobiological model for PPD, promoting normalization of MAO-A levels after the immediate postpartum period might reduce the probability of developing the full clinical disorder.”

Newsletters

Receive the latest pathology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

References

  1. J. Sacher et al., “Relationship of Monoamine Oxidase-A Distribution Volume to Portpartum Depression and Postpartum Crying”, Neuropsychopharmacology (2014). doi:10.1038/npp.2014.190 [Epub ahead of print].

About the Author(s)

Roisin McGuigan

I have an extensive academic background in the life sciences, having studied forensic biology and human medical genetics in my time at Strathclyde and Glasgow Universities. My research, data presentation and bioinformatics skills plus my ‘wet lab’ experience have been a superb grounding for my role as an Associate Editor at Texere Publishing. The job allows me to utilize my hard-learned academic skills and experience in my current position within an exciting and contemporary publishing company.

More Articles by Roisin McGuigan

Explore More in Pathology

Dive deeper into the world of pathology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement

Recommended

False

Related Content

The Shapeshifting Cancer
Neurology
The Shapeshifting Cancer

February 24, 2022

1 min read

Understanding the heterogeneity and plasticity of glioblastoma

Image of the Month
Neurology
Image of the Month

October 21, 2016

1 min read

Who Will Be The Caretakers?
Neurology
Who Will Be The Caretakers?

August 4, 2022

3 min read

Recent allegations of image manipulation in a major Alzheimer’s disease paper reaffirm the importance of research integrity

Getting to the Genetic Core of Autism
Neurology
Getting to the Genetic Core of Autism

August 15, 2022

2 min read

Investigating the genotype-phenotype relationship in autism to improve our understanding of heterogeneity

False

The Pathologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.